Health Care/Hospital

Innovative strides in medical-grade TPUs: ICP DAS-BMP to introduce groundbreaking solutions at CMEF and Medtec Japan

HSINCHU, March 27, 2024 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), Asia's leading medical TPU (thermoplastic polyurethane) manufacturer and supplier, will exhibit at the International Component Manufacturing and Design Show (ICMD, part of CMEF) and Medtec Japan inApril 2024. The company w...

2024-03-27 09:20 514

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy

ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology a...

2024-03-27 08:00 426

Beauty Industry's Largest Acquisition to Date in 2024, Beauty Farm Acquires 70% of Naturade, China's Second-Largest Industry Player

HONG KONG, March 27, 2024 /PRNewswire/ -- Beauty Farm Medical and Health Industry Inc. ("Beauty Farm" or the "Company")(02373.HK), one of China's largest beauty and wellness service providers and aesthetics medical brands, is pleased to announce its acquisition of a 70% equity interest in the cor...

2024-03-27 07:30 933

Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology

SEONGNAM, South Korea and AURORA, Colo., March 26, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) , a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr.Raul...

2024-03-27 06:00 185

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

LONDON, March 27, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma pro...

2024-03-27 05:59 313

Keymed Biosciences Announces 2023 Annual Results and Business Updates

* Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by theChina's NMPA and granted priority review. * Advanced a Phase III clinical study of Stapokibart for the treatment of CRSwNP in 2023. The results of t...

2024-03-27 01:16 506

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

EPLive 2024 is a two-day conference that draws the world's top cardiac electrophysiology experts AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on co...

2024-03-26 23:58 263

Datasea Enters into 5G AI Multimodal Communication Cooperation Agreement Expected to Expand its China 5G Services Revenue

The Agreement with an Estimated Value of $30 Million Supports its Revenue Guidance of$86 Million, a 1,128% Year-Over-Year Increase for its Full Fiscal Year BEIJING, March 26, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative ...

2024-03-26 22:00 723

WuXi Biologics Reports Solid 2023 Annual Results

Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Million Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong Momentum Sustained Non-COVID Late-Phase and Commercial Manufacturing Revenue Grew by 101.7% Y-o-Y "R" in CRDMO Thrived with Extended Part...

2024-03-26 21:53 823

ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis

LYON, France, March 26, 2024 /PRNewswire/ -- Reportlinker announces the release of the report "A White Paper To Understand The Market Structure Of Pediatric Pertussis Hexavalent and Combination Vaccines

2024-03-26 21:00 626

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

- New research published in Clinical Cancer Research shows significant improvement in distant recurrence-free survival with combined durvalumab and tremelimumab treatment, supported by Lunit SCOPE IO's analysis of tumor microenvironment SEOUL, South Korea, March 26, 2024 /PRNewswire/ -- Lunit (K...

2024-03-26 21:00 536

PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition

NANJING, China, March 26, 2024 /PRNewswire/ -- PharmaBlock (Stock code: 300725.SZSE), a global, fully integrated CRDMOwith a focus on innovative chemistry and low-carbon manufacturing, is proud to announce that it has been awarded the 2024 CMO Excellence in Green Chemistry Award by the American ...

2024-03-26 20:00 577

TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

* TU7710 has the potential to be a highly effective and long-acting treatment for bleeding episodes as well as for preventing bleeding during surgery or invasive procedures in hemophilia patients with inhibitors * Interim results from an ongoing Phase 1a study in healthy male volunteers will ...

2024-03-26 20:00 526

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

* MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events * Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of t...

2024-03-26 19:00 682

Beauty Farm Announces 2023 Annual Results

Revenue and Net Profit Reached Record High Acquisition of Naturade, China's Second-Largest Market Share Brand HONG KONG, March 26, 2024 /PRNewswire/ -- Beauty Farm Medical and Health Industry Inc. ("Beauty Farm" or the "Company") (02373.HK), one of the largest beauty and wellness services provide...

2024-03-26 18:25 1332

ANICAV Promotes Sustainability and Wellbeing with Veganism with Legumes from Europe project

SYDNEY, March 26, 2024 /PRNewswire/ -- The Legumes from Europe project, promoted by ANICAV, aims to boost consumption inAustralia of high-quality canned legumes from the "Old Continent". Among the many objectives, improving environmental sustainability and personal well-being and protecting the p...

2024-03-26 18:19 823

Waterdrop Inc. Announces Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results and a Special Cash Dividend

BEIJING, March 26, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three months and full year en...

2024-03-26 18:00 1037

Minesto presents today at Naventus Renewables Summit, Stockholm

GOTHENBURG, Sweden, March 26, 2024 /PRNewswire/ -- Minesto's CEO Dr Martin Edlund presents today at Naventus Renewables Summit held in Stockholm, 26 March 2024.   The event is livestreamed, and Minesto will be presenting at 14.40 CET:   Naventus & Partners Renewables Summit 2024 For additional ...

2024-03-26 17:56 672

Cicada Innovations launches HealthTech Hub in Western Sydney's "hidden innovation ecosystem"

SYDNEY, March 26, 2024 /PRNewswire/ -- Australia's flagship deep tech incubator  Cicada Innovations is officially opening the doors to the "Cicada HealthTech Hub " on 25 March 2024, officiated...

2024-03-26 10:00 872

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033

SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed inAustralia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody,...

2024-03-26 09:57 909
12345 ... 802

Week's Top Stories